

Drugs@FDA: FDA Approved Drug Products

f **SHARE** ([HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020825](https://www.facebook.com/sharer/sharer.php?u=http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=020825))

t **TWEET** ([HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=DRUGS@FDA: FDA APPROVED DRUG PRODUCT S&URL=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCE SS&APPLNO=020825](https://twitter.com/intent/tweet/?text=Drugs@FDA: FDA Approved Drug Product S&url=http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.proce ss&applno=020825))

in **LINKEDIN** ([HTTPS://WWW.LINKEDIN.COM/SHAREARTICLE?MINI=TRUE&URL=HTTP://WWW.ACCESSDAT A.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020825&TITLE=DRUG S@FDA: FDA APPROVED DRUG PRODUCTS&SOURCE=FDA](https://www.linkedin.com/sharearticle?mini=true&url=http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=020825&title=Drug S@FDA: FDA Approved Drug Products&source=fda))

@ **PIN IT** ([HTTPS://WWW.PINTEREST.COM/PIN/CREATE/BUTTON/?URL=HTTP://WWW.ACCESSDATA.FDA.G OV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020825&DESCRIPTION=DRUG S@FDA: FDA APPROVED DRUG PRODUCTS](https://www.pinterest.com/pin/create/button/?url=http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=020825&description=Drug S@FDA: FDA Approved Drug Products))



✉ **EMAIL** ([MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.AC CESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020825](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=020825))

🖨 **PRINT**

[Home \(index.cfm\)](#) | [Previous Page](#)

New Drug Application (NDA): 020825

Company: PFIZER

Drug Name(s):

- GEODON (ZIPRASIDONE HYDROCHLORIDE)

✉ **EMAIL** ([MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.AC CESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS%26VARAPPLNO=020 825](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process%26varapplno=020825))

- **Corrected Approval Letter**
(http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20825s009ltr.pdf)
- **Other Important Information from FDA**
(<http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm094303.htm>)

Products on NDA 020825



CSVExcelPrint

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code
GEODON	ZIPRASIDONE HYDROCHLORIDE	EQ 20MG BASE	CAPSULE;ORAL	Prescription	Yes	AB
GEODON	ZIPRASIDONE HYDROCHLORIDE	EQ 40MG BASE	CAPSULE;ORAL	Prescription	Yes	AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code
GEODON	ZIPRASIDONE HYDROCHLORIDE	EQ 60MG BASE	CAPSULE;ORAL	Prescription	Yes	AB
GEODON	ZIPRASIDONE HYDROCHLORIDE	EQ 80MG BASE	CAPSULE;ORAL	Prescription	Yes	AB

Showing 1 to 4 of 4 entries

Approval Date(s) and History, Letters, Labels, Reviews for NDA 020825 

Labels for NDA 020825 

Therapeutic Equivalents for NDA 020825 